Vincristine (sulfate)

Vincristine (sulfate)

• CAS Number: 2068-78-2
• UNSPSC Description: Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
• Target Antigen: Apoptosis; Microtubule/Tubulin
• Type: Natural Products
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/vincristine-sulfate.html
• Purity: 99.81
• Solubility: DMSO : 83.33 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : 50 mg/mL (ultrasonic)
• Smiles: CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O
• Molecular Weight: 923.04
• References & Citations: [1]Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.|[2]Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87.|[3]Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7.|[4]Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000.|[5]Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7.|[6]Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108.Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Acta Pharmacol Sin. 2024 Jun 6.|Am J Cancer Res. 2021 Apr 15;11(4):1428-1445.|bioRxiv. 2023 Jul 25.|bioRxiv. 2023 Jun 3.|bioRxiv. 2023 Sep 16.|bioRxiv. 2024 July 04.|Br J Cancer. 2024 Aug 22.|Cancer Commun (Lond). 2024 Apr;44(4):469-490.|Cancer Immunol Res. 2023 May 3;11(5):583-599.|Cancers (Basel). 2021, 13(13), 3323.|Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8.|Cell Commun Signal. 2024 Jun 13;22(1):325.|Cell Rep Med. 2024 Mar 19;5(3):101468.|Cell. 2024 Apr 25;187(9):2288-2304.e27.|Eur J Med Chem. 2018 Feb 25;146:157-170.|Front Microbiol. 2019 May 9;10:939. |Front Oncol. 2021 Apr 22;11:665763.|Front Oncol. 2021 Apr 6.|Front Oncol. 2024 Jul 19:14:1440650.|Hum Exp Toxicol. 2021 Feb 4;960327121991901.|Int J Biol Macromol. 2019 Jan 30;128:574-582.|Int J Nanomedicine. 2017 Mar 16;12:2081-2108.|J Chromatogr B. 2021, 122591.|J Clin Invest. 2024 Mar 7:e172716.|Leuk Lymphoma. 2020 Feb;61(2):420-428.|Leukemia. 2021 Mar 29.|Mol Cancer. 2024 Jan 10;23(1):12.|Mol Ther. 2021 Jul 1;S1525-0016(21)00353-1.|Neurobiol Learn Mem. 2019 Sep;163:107038.|Oncotarget. 2017 Dec 2;8(68):112313-112329.|Pharmacol Res. 2024 May 9:204:107208.|PLoS Biol. 2024 June 27.|Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2208457119.|Sci Adv. 2023 Feb 10;9(6):eade9238.|Sci Rep. 2019 Aug 12;9(1):11677.|SLAS Discov. 2024 Feb 12;29(2):100147.|Biochem Biophys Res Commun. 2023 Jun 27;674:27-35.|Biomed Pharmacother. 2020 May;125:110003.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27.|bioRxiv. 2019 Dec.|Breast Cancer Res Treat. 2023 May 19.|Cancers (Basel). 2022 Oct 19;14(20):5127.|Cell Mol Immunol. 2023 Jan;20(1):51-64.|DRUG RESIST UPDATE. 2023 Feb 13;68:100951.|Front Oncol. 2020 Mar 13;10:308.|Front Pharmacol. 15 July 2022.|J Biomed Inform. 2023 May 15;104383.|J Transl Med. 2023 Jan 9;21(1):9.|Mol Pharm. 2022 Oct 21.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched